SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Cardiome Reports Second Quarter 2014 Financial Results

NASDAQ: CRME
TSX: COM

Cardiome to conduct conference call and webcast today, August 11, at 8:00 a.m. Eastern (5:00 a.m. Pacific)

VANCOUVER, Aug. 11, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the second quarter and six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP). All share and per share amounts reflect the one-for-five share consolidation that occurred on April 12, 2013.

"Cardiome's financial results for the second quarter and first six months of 2014 are on track with our plan," stated William Hunter, M.D., Cardiome's president and CEO. "Sales for Brinavess continued to advance in response to our marketing and promotional efforts, but, as expected, were offset by the gradual sales decline for Aggrastat in the face of generic competition. In future quarters, we expect sales for Cardiome overall will increase as growth for Brinavess exceeds the erosion for Aggrastat."

Summary Results
Cardiome recorded a net loss of $4.2 million ($0.26 per common share) for the three months ended June 30, 2014 (Q2-2014), compared to a net loss of $2.8 million ($0.22 per common share) for the three months ended June 30, 2013 (Q2-2013).

Total revenue for Q2-2014 was $7.7 million compared to $0.1 million in Q2-2013. In Q2-2014, revenues from the sale of BRINAVESS™ and AGGRASTAT® were $6.5 million, and licensing, royalty and other fees were $1.2 million. In Q2-2013, revenue was comprised of licensing and other fees received from Merck, our former collaborative partner.

Cost of goods sold for Q2-2014 was $2.2 million. No cost of goods sold was recorded for Q2-2013, as Cardiome did not have any product sales in Q2-2013.

Selling, general and administration expenditures for Q2-2014 were $8.8 million compared to $3.0 million for Q2-2013. The increase was primarily due to higher costs associated with sales and marketing efforts to support the commercialization of BRINAVESSTM and the continued sales of AGGRASTAT®, and certain one-time costs.

Liquidity and Outstanding Share Capital
At June 30, 2014, Cardiome had cash and cash equivalents of $9.4 million. As of August 7, 2014, the company had 16,520,072 common shares issued and outstanding and 1,138,312 common shares issuable upon the exercise of outstanding stock options at a weighted-average exercise price of CAD $4.42 per share.

Conference Call
Cardiome will hold a teleconference and webcast on Monday, August 11, 2014 at 8:00 a.m. Eastern (5:00 a.m. Pacific). To access the conference call, please dial 416-764-8688 or 888-390-0546 and use conference ID 04422550. The webcast can be accessed through Cardiome's website at www.cardiome.com.

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through September 8, 2014. Please dial 416-764-8677 or 888-390-0541 and enter code 422550# to access the replay.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer  
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions.  Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2014 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

 

CARDIOME PHARMA CORP.
Consolidated Statements of Operations and Comprehensive Income (Loss)
(Unaudited)
(Expressed in thousands of U.S. dollars, except share and per share amounts)
(Prepared in accordance with U.S. GAAP)





Three months ended

Six months ended


June 30,
2014

June 30,
2013

June 30,
2014

June 30,
2013

Revenue:






Product revenues

$

6,500

$

-

$

13,062

$

-


Licensing, royalty and other fees

1,167

107

2,197

167


7,667

107

15,259

167

Cost of goods sold

2,243

-

3,736

-


5,424

107

11,523

167

Expenses:






Selling, general and administration

8,808

2,974

16,807

5,210


Amortization

564

108

1,100

216


Research and development

59

35

304

405


Restructuring

-

(57)

-

(130)


9,431

3,060

18,211

5,701

Operating loss

(4,007)

(2,953)

(6,688)

(5,534)






Other (income) expense:






Interest (income) expense

226

(11)

480

(27)


Gain on settlement of debt

-

-

-

(20,834)


Other income

(18)

(176)

(117)

(328)


Foreign exchange (gain) loss

(131)

8

50

36


77

(179)

413

(21,153)

Net income (loss) before income taxes

(4,084)

(2,774)

(7,101)

15,619

Provision for income taxes

156

-

273

-

Net income (loss)

$

(4,240)

$

(2,774)

$

(7,374)

$

15,619

Other comprehensive income:






Foreign currency translation adjustments

2

-

164

-

Comprehensive income (loss)

$

(4,238)

$

(2,774)

$

(7,210)

$

15,619

Earnings (loss) per common share







Basic and diluted

$

(0.26)

$

(0.22)

$

(0.46)

$

1.25

Weighted average common shares outstanding







Basic

16,520,072

12,470,335

15,931,887

12,470,335



Diluted

16,520,072

12,470,335

15,931,887

12,491,987






 

 

CARDIOME PHARMA CORP.
Consolidated Balance Sheets
(Unaudited)
(Expressed in thousands of U.S. dollars, except share amounts)
(Prepared in accordance with U.S. GAAP)







June 30,

2014

December 31,

2013




Assets

 



Current assets:




Cash and cash equivalents

$

9,353

$

10,984


Restricted cash

2,428

2,323


Accounts receivable, net of allowance for doubtful accounts of

$552 (December 31, 2013 - $325)

7,313

6,674


Inventories

6,455

6,597


Prepaid expenses and other assets

3,034

1,749


28,583

28,327




Property and equipment

564

618

Intangible assets

17,093

18,069

Goodwill

318

318


$

46,558

$

47,332




Liabilities and Stockholders' Equity

 



Current liabilities:




Accounts payable and accrued liabilities

$

9,327

$

14,003


Current portion of deferred consideration

4,769

3,688


14,096

17,691




Deferred consideration

4,317

6,997


18,413

24,688




Stockholders' equity:




Common stock

284,518

272,083



Authorized - unlimited number with no par value





Issued and outstanding – 16,520,072 (2013 – 14,958,277)




Additional paid-in capital

33,625

33,349


Deficit

(308,120)

(300,746)


Accumulated other comprehensive income

18,122

17,958


28,145

22,644


$

46,558

$

47,332

 

 

CARDIOME PHARMA CORP.
Consolidated Statements of Cash Flows
(Unaudited)
(Expressed in thousands of U.S. dollars)
(Prepared in accordance with U.S. GAAP)





Three months ended

Six months ended


June 30,
2014

June 30,
2013

June 30,
2014

June 30,
2013

Operating activities:





Net income (loss) for the period                 

$

(4,240)

$

(2,774)

$

(7,374)

$

15,619

Items not affecting cash:






Amortization

564

108

1,100

216


Stock-based compensation

170

123

396

216


Gain on settlement of debt

-

-


(20,834)


Unrealized foreign exchange (gain) loss

(105)

-

(50)

24


Other

-

(39)

-

(12)

Changes in operating assets and liabilities:






Restricted cash

(91)

-

(116)

-


Accounts receivable

(187)

(338)

(696)

453


Inventories

959

(2,800)

120

(2,800)


Prepaid expenses and other assets

(151)

(85)

(1,305)

(118)


Accounts payable and accrued liabilities

(247)

(237)

(4,699)

(1,288)

Net cash used in operating activities

(3,328)

(6,042)

(12,624)

(8,524)






Investing activities:






Purchase of property and equipment

(14)

(13)

(17)

(13)


Purchase of intangible assets

(40)

(22)

(52)

(40)

Net cash used in investing activities

(54)

(35)

(69)

(53)






Financing activities:






Issuance of common stock, net of share
issue costs

(4)

-

12,406

-


Proceeds from sale of property and
equipment

-

55

-

79


Repayment of long-term debt

-

-

-

(13,000)


Payment of deferred consideration

(728)

-

(1,599)

-

Net cash (used in) provided by financing activities

(732)

55

10,807

(12,921)

Effect of foreign exchange rate changes on cash
and cash equivalents

231

(18)

255

(62)

Decrease in cash and cash equivalents during
the period

(3,883)

(6,040)

(1,631)

(21,560)

Cash and cash equivalents, beginning of period

13,236

25,747

10,984

41,267

Cash and cash equivalents, end of period

$

9,353

$

19,707

$

9,353

$

19,707






Supplemental cash flow information:





Interest paid

$

247

$

-

$

543

$

-

Interest received

-

11

-

27

Net income taxes paid

135

-

180

-

 

SOURCE Cardiome Pharma Corp.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.